Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. - Wikidata - awgldk - TriplyDB

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

http://www.wikidata.org/entity/Q37425090

about

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function Identification of a Src kinase SH3 binding site in the C-terminal domain of the human ErbB2 receptor tyrosine kinase Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer The PTEN tumor suppressor gene and its role in lymphoma pathogenesis Progress of molecular targeted therapies for prostate cancers Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer The dynamic nature of the kinome In vitro and in vivo models for analysis of resistance to anticancer molecular therapies Targeting Src family kinases in anti-cancer therapies: turning promise into triumph Signaling cross-talk in the resistance to HER family receptor targeted therapy Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Prediction of drug combinations by integrating molecular and pharmacological data Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Tyr724 phosphorylation of ELMO1 by Src is involved in cell spreading and migration via Rac1 activation.Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data.p53 in cell invasion, podosomes, and invadopodia Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.

P2860

Q24295164-3A03457A-1D1D-4028-9713-60DAAA416693 Q24297527-8ED9F9C5-88B9-45C3-BC84-0813E8610D09 Q26753162-D5793ECE-2A18-4D85-A40F-6C4E730450A2 Q26772969-C4C80801-59C8-47AA-8C2A-DB9271200C98 Q26773907-F4136CB6-5380-4B6A-AC2C-BEA17FD9A89D Q26776527-C7AB781C-B520-407A-950A-CCAF1BFEE04D Q26823014-CAB9DBF5-AEC2-4165-AFDA-4287B5F4B1B8 Q26852215-A4E8A752-6EC3-4EDF-9670-29408DB0D86C Q26852588-931E3499-024F-4DEF-A3B7-CBE954CC7457 Q27014174-356F5764-7F46-4DA4-90FB-35D80EA640BC Q27025646-56AFEB16-3EDC-4DED-933B-27AB4687671E Q27027778-25831C07-9335-4344-8C6B-9E550F683701 Q27315979-6C94C001-F365-453C-ADED-5E94415932C8 Q27853122-605F789B-CC5E-4325-B893-69AC8C66A19A Q28478623-6FEDAA20-DE6D-423C-92F7-4E382BB14B63 Q28544422-83843DE3-7050-4CD3-900E-7C36EC3940A7 Q29248612-AD5A538B-B606-484F-9DB2-0BD118015600 Q30278774-9176B8B3-28B5-454E-80DB-DA3419B5BF61 Q30412086-2FAC7E91-1E14-4E36-803A-0ADE4AEDDA34 Q30465097-C7C94012-CD2A-4F48-8185-107DAE22A1B9 Q30658863-8D67F46D-E1B1-42C0-B1D0-8B8983DC872E Q30679405-B8F4FF32-9C40-4E86-8C6B-CC14D7DC6AE4 Q30724810-F17DEBDF-57C3-4E6B-BBA3-3439DED6505E Q31038214-D47F6E08-BD56-448C-A8D3-B7FE72D1D1EF Q31041986-180A6703-555E-43B2-90A4-29AE48FC56C5 Q33358202-0A27F0ED-61EF-42DF-94CD-EEE114CC2D08 Q33555302-49CF7C46-601B-4634-9B10-A61210874FA3 Q33571352-200F1BAC-60EB-404B-9632-47BD9DC46BAD Q33580500-3E968471-AEFA-487A-95E2-A9DE0051376D Q33601653-BE78871A-12A5-43A0-AC49-180845A04DC6 Q33668653-D9F605F8-4F1B-47B5-A5D3-17C97EDBD161 Q33737278-C42F4F3A-672B-4676-BB68-925051D90EDC Q33739297-85773032-E88C-4C21-82E3-C37674762303 Q33776733-BFAA3C51-89BE-47A7-953E-596E4996A857 Q34023704-FC38EA94-D208-4C45-B8D5-9941B0E19377 Q34051933-C500188F-91A5-4099-938A-1198E32E7ABB Q34169595-AC581493-5614-457E-A747-83104EDEB122 Q34182834-C52FF68D-D3C5-4C58-9583-4947D6F8FA71 Q34211720-8189E6A0-0489-447D-982A-8E4ACCB38623 Q34308692-020FA0DD-DAEC-401F-91A7-66D992DF2387

P2860

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

http://www.wikidata.org/entity/Q37425090

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combating trastuzumab resistan ...... multiple resistance pathways.

@en

Combating trastuzumab resistan ...... multiple resistance pathways.

@nl

type

label

Combating trastuzumab resistan ...... multiple resistance pathways.

@en

Combating trastuzumab resistan ...... multiple resistance pathways.

@nl

prefLabel

Combating trastuzumab resistan ...... multiple resistance pathways.

@en

Combating trastuzumab resistan ...... multiple resistance pathways.

@nl

P1433

Q37425090-E9503A06-2EAF-477D-8ED0-09CFED4E87C5

P1476

Q37425090-7DEE7D62-12F1-4361-9871-80D57B04652D

P2093

Q37425090-0C7B2AA8-EE1C-4458-BF82-A3F7911AEC14

Q37425090-2240E86A-F748-40C2-B8B8-B89269A1F456

Q37425090-273F2AEA-85BF-4B7A-AB63-8DB2E7C45E64

Q37425090-36CB13FB-DE86-476A-9344-764FD8465DF1

Q37425090-3A52BC87-DE71-45C6-B1E3-6128E74B1AD5

Q37425090-3C6B1217-1660-4A88-855D-472C800ECEC4

Q37425090-6267758A-CEE8-49A9-86A8-752D264C23C0

Q37425090-89B4D417-FA66-4279-9D0C-505D717C1ED0

Q37425090-8FFE5739-A1B9-473A-90A8-8D076CBCDF0D

Q37425090-979564D1-24FB-4B24-9FCC-F63C44DAC0A8

P2860

Q37425090-0287C9CF-A9E1-4E46-83B6-E1620DC85028

Q37425090-0494DF2D-ACC5-419A-8222-824C0FA660AF

Q37425090-10B6DAB3-3D6B-4782-B1E7-D1FC849BAD55

Q37425090-154E728A-1992-4D7E-B20D-6CDD007F6238

Q37425090-167CB6E0-BD7C-4C64-A621-F6FCB2F1686E

Q37425090-16DA7C19-BCE8-4A71-9DF9-BCD0EE4419D5

Q37425090-247A8C71-CDB6-4212-9C77-93E151D9F04A

Q37425090-2A535D08-92C7-4F14-A446-F45C783C5506

Q37425090-2ED8EDD7-2DB5-4ABA-BD69-46666CA205EB

Q37425090-33B16E6C-FEB1-46CE-8A1B-FADEB9420EA0

P2888

Q37425090-135A59ED-3EA0-4AE9-A700-1094744F7B11

P304

Q37425090-6CAE7A5E-7B4E-4392-8464-B9932258BF37

P31

Q37425090-C11026B7-6976-411D-B428-C6DC2B4BAE93

P356

Q37425090-5C0E7D0A-00D2-4439-BD5D-5775DD30F6F8

P407

Q37425090-7C94FA19-2D98-475A-AD1B-14800C8478FE

P433

Q37425090-5C8268A3-83FA-4D67-AF0B-0CA3F42D523E

P478

Q37425090-1A259DAE-127D-4443-A7A0-B0414EA7DE16

P577

Q37425090-28913DF6-D51C-4EED-BA96-3C8063B880F5

P5875

Q37425090-45B21958-6548-4AD2-8BB8-F676200545C7

P6179

Q37425090-E281A185-9A42-4A9F-A010-8C2028D34B92

P698

Q37425090-266AFCEF-5FB9-4DA6-B0A5-7EA6992C1038

P932

Q37425090-1C421C01-1092-4B29-BA9E-EAF4A9E64BED

P356

P1433

Nature Medicine

P1476

Combating trastuzumab resistan ...... multiple resistance pathways.

@en

P2093

Aysegul A Sahin

http://www.w3.org/2001/XMLSchema#string

Dihua Yu

http://www.w3.org/2001/XMLSchema#string

Francisco J Esteva

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Hua Guo

http://www.w3.org/2001/XMLSchema#string

Ling-Ming Tseng

http://www.w3.org/2001/XMLSchema#string

Ping Li

http://www.w3.org/2001/XMLSchema#string

Samuel W Brady

http://www.w3.org/2001/XMLSchema#string

Say-Bee Poh

http://www.w3.org/2001/XMLSchema#string

Shau-Hsuan Li

http://www.w3.org/2001/XMLSchema#string

P2860

ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly

P2888

P304

461-469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2309

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50377268

http://www.w3.org/2001/XMLSchema#string

P6179

1025284851

http://www.w3.org/2001/XMLSchema#string

P698

21399647

http://www.w3.org/2001/XMLSchema#string

P932

3877934

http://www.w3.org/2001/XMLSchema#string